A Large Polypill Clinical Trial Shows a Third Reduction in Cardiovascular Events

The research and medical communities are slow to undertake work on combination therapies. Regulation makes it exceedingly expensive to assess multiple combinations, and there are numerous other perverse incentives to challenge any effort to build combination therapies with components developed and manufactured by different groups. Short of working around the existing system of regulation, and methods of doing this at scale are lacking at the present time, this is a challenging problem to solve. People follow incentives. Given this, it it is entirely plausible that there are many largely unexplored instances in which existing classes of medication for age-related disease might synergize to be more effective together. In this context, clinicians and researchers have been discussing polypills for quite some time. The term polypill usually means

From http://besthealthnews.com/2019/08/a-large-polypill-clinical-trial-shows-a-third-reduction-in-cardiovascular-events/?utm_source=rss&utm_medium=rss&utm_campaign=a-large-polypill-clinical-trial-shows-a-third-reduction-in-cardiovascular-events

from
https://healthnews010.wordpress.com/2019/08/31/a-large-polypill-clinical-trial-shows-a-third-reduction-in-cardiovascular-events/

From https://jamesjohnson10.blogspot.com/2019/08/a-large-polypill-clinical-trial-shows.html

from
https://jamesjohnson10.wordpress.com/2019/08/31/a-large-polypill-clinical-trial-shows-a-third-reduction-in-cardiovascular-events/